Table 1.
Clinical trials of ICIs therapy for HCC the last three years (www.clinicaltrails.com).
| NCT ID | Phase | Interventions | Country |
|---|---|---|---|
| NCT04943679 | 1, 2 | Anti-PD-1/PD-L1/PEG-IFN-α | China |
| NCT03638141 | 2 | Durvalumab/Tremelimumab | US |
| NCT04165174 | 2 | Terepril monoclonal antibody/Apatinib | China |
| NCT04696055 | 2 | Regorafenib in combination with Pembrolizumab | US |
| NCT04728321 | 2 | Anti-PD-1/CTLA-4 bispecific antibody AK104/Lenvatinib | China |
| NCT04444167 | 1, 2 | Anti-PD-1/CTLA-4 bispecific antibody AK104/Lenvatinib | China |
| NCT04193696 | 2 | Radiation therapy and systemic anti-PD-1 immunotherapy | China |
| NCT03869034 | 2 | Transarterial Infusion Chemotherapy Combined With PD-1 Inhibitor | China |
| NCT04974281 | 1 | Anti-PD-1 and Lenvatinib Plus TACE | China |
| NCT04418401 | 1 | Donafinib Combined With Anti-PD-1 Antibody | China |
| NCT04814043 | 2 | Anti-PD-1 and lenvatinib plus TACE and chemotherapy | China |
| NCT04814030 | 2 | Anti-PD-1 Plus Chemoembolization and chemotherapy | China |
| NCT04273100 | 2 | Anti-PD-1 combined with TACE and lenvatinib | China |
| NCT03605706 | 3 | Camrelizumab (PD-1 Antibody) in Combination With chemotherapy | China |
| NCT03839550 | 2 | Apatinib mesylate +PD-1 antibody SHR-1210 | China |
| NCT04564313 | 1 | Anti-PD-1 Antibody Camrelizumab | China |
| NCT04233840 | 2 | Nivolumab (PD-1 Antibody) | China |
| NCT04297280 | 2 | Anti-PD-1 Antibody (IBI308) Combined With TACE | China |
| NCT04229355 | 3 | DEB-TACE plus PD-1 inhibitor | China |
| NCT03857815 | 2 | Radiation Combined With Anti-PD-1 Antibody (IBI308) | China |
| NCT04639284 | NA | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | China |
| NCT04518852 | 2 | TACE combined with sorafenib and PD-1 mAb | China |
| NCT04172571 | 2 | anti-PD-1 antibody AK105 plus anlotinib hydrochloride | China |
| NCT03939975 | 2 | anti-PD-1 therapy in combination with incomplete thermal ablation | China |
| NCT04248569 | 1 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab | US |
| NCT04802876 | 2 | Spartalizumab (PD-1 inhibitor) | Spain |
| NCT04191889 | 2 | Hepatic Arterial Infusion combined with Apatinib and Camrelizumab | China |
| NCT03829501 | 1, 2 | anti-ICOS mAb (KY1044) in combination with anti-PD-L1 mAb (atezolizumab) | US |
| NCT03652077 | 1 | INCAGN02390 (TIM3 inhibitor) | US |
| NCT03836352 | 2 | DPX-Survivac, in Combination Cyclophosphamide, Pembrolizumab, | US |
| NCT03849469 | 1 | XmAb®22841 in Combination with Pembrolizumab | US |
| NCT04709380 | 3 | Radiotherapy Plus Toripalimab | China |
| NCT04167293 | 2, 3 | Sintilimab and Stereotactic Body Radiotherapy | China |
| NCT04157985 | 3 | PD-1/PD-L1 Inhibitors | US |
| NCT04658147 | 1 | Perioperative Nivolumab With or Without Relatlimab | US |
| NCT03713593 | 3 | Lenvatinib in Combination With Pembrolizumab | US |
| NCT04629339 | 2 | INCB086550 (Oral PD-L1 Inhibitor) | Bulgaria |
| NCT04487704 | NA | camrelizumab | China |
| NCT04114136 | 2 | Anti-PD-1 mAb Plus Metabolic Modulator | US |
| NCT04785287 | 1, 2 | Anti-CTLA4 mAb, Nivolumab, and Stereotactic Body Radiation | US |
| NCT04116320 | 1 | Focused Ultrasound Ablation and PD-1 Antibody Blockade | US |
| NCT04740307 | 2 | pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib | US |
| NCT04665609 | 3 | Thermal Ablation, Anlotinib and TQB2450 (PD-L1 inhibitor) | China |
| NCT03867084 | 3 | Pembrolizumab (PD-1 inhibitor) | US |
| NCT04246177 | 3 | lenvatinib and pembrolizumab in combination with TACE | US |
| NCT03655613 | 1, 2 | PD-1 inhibitor(APL-501 or nivolumab) + c-Met inhibitor (APL-101) | Australia |
| NCT04052152 | 2 | Anlotinib Hydrochloride Capsules combined with Sintilimab injection | China |
| NCT04204577 | 2 | Thermal Ablation, Apatinib and PD-1 Antibody SHR-1210 | China |
| NCT04102098 | 3 | Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab | US |
| NCT04828486 | 2 | Futibatinib and Pembrolizumab | US |
| NCT03785210 | 2 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin | US |
| NCT03949231 | 3 | PD1/PDL1 Inhibitor | China |
| NCT03680508 | 2 | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) | US |
| NCT03973112 | 2 | HLX10 in Combination With HLX04 | China |
| NCT04912765 | 2 | Neoantigen Dendritic Cell Vaccine and Anti-PD1 (Nivolumab) | China |
| NCT03859128 | 2, 3 | Toripalimab (PD-1 Antibody) | China |
| NCT04926532 | 1, 2 | Toripalimab (PD-1 Antibody) Plus Sorafenib | China |
| NCT03722875 | NA | SHR-1210 (PD-1 Antibody) Plus Apatinib | China |
| NCT04014101 | 2 | Anti-PD-1 Antibody SHR-1210 Combined With Apatinib Mesylate | China |
| NCT04947826 | 2 | combination therapy of HAIC with PD-1 antibody and VEGF antibody | China |
| NCT04411706 | 2 | Anti-PD-1 Antibody combined with apatinib and capecitabine | China |
| NCT03764293 | 3 | Anti-PD-1 Antibody SHR-1210 Combined With Apatinib Mesylate | China |
| NCT03793725 | 2 | Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib | China |
| NCT04297202 | 2 | Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib | China |
| NCT04393220 | 2 | Combination of PD-1 and VEGFR-2 Blockade | China |
| NCT04665362 | 1 | Oncolytic Virus M1Combined With Anti-PD-1 Antibody and Apatinib | China |
| NCT03966209 | 1 | JS001(PD-1 inhibitor) | China |
| NCT03732547 | 2 | Anti-PD-1 Antibody Combined With PolyIC | China |
NA, Not available.